Bowman & Co S.C. Reduces Position in IQVIA Holdings Inc. (NYSE:IQV)

Bowman & Co S.C. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 12.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 4,712 shares of the medical research company’s stock after selling 691 shares during the quarter. Bowman & Co S.C.’s holdings in IQVIA were worth $926,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the stock. Private Trust Co. NA increased its holdings in IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after acquiring an additional 47 shares in the last quarter. Clear Harbor Asset Management LLC increased its stake in shares of IQVIA by 1.3% in the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock worth $941,000 after purchasing an additional 50 shares in the last quarter. Pine Valley Investments Ltd Liability Co lifted its stake in shares of IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after buying an additional 50 shares in the last quarter. Fortitude Family Office LLC boosted its holdings in IQVIA by 2.9% in the 3rd quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock worth $468,000 after buying an additional 56 shares during the period. Finally, Huntington National Bank raised its holdings in IQVIA by 7.4% during the third quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after acquiring an additional 56 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $197.25 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The stock has a market cap of $35.80 billion, a PE ratio of 25.89, a P/E/G ratio of 2.09 and a beta of 1.48. The company has a 50-day moving average price of $200.09 and a 200 day moving average price of $221.29.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent analyst reports. Barclays dropped their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Truist Financial lowered their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. The Goldman Sachs Group cut their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Robert W. Baird decreased their price target on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $255.82.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.